| Detailed information |
|---|
| CancerLivER ID | 2197 |
| Biomarker | miR-101-3p, miR-106b-3p |
| Biomarker Name/Symbol (given in Publication) | miR-101-3p + miR-106b-3p |
| Biomolecule | miRNA |
| Subject | Human |
| Degree of Validity | Potential diagnostic marker for HCC and validated on independent dataset |
| Experimental Condition | HCC v/s Cirrhosis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC |
| Level of significance | p < 0.001 |
| Source | Serum |
| PMID | 29632649 |
| Type of Biomarker | Diagnostic |
| Pathway | cancer- associated processes |
| Cohort | 62 clinically diagnosed HCC patients, 41 patients with liver cirrhosis and 25 healthy controls (not affected by liver diseases or any neoplastic disorder) from various Institutions, between April 2012 and November 2015. |
| Sensitivity | 84.6 |
| Specificity | 94.1 |
| Accuracy | 90 |
| AUC | 0.96 |
| Disease | Human HCC, Cirrhosis |
| Year of Publication | 2018 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |